Johnson & Johnson (JNJ) Rises As Market Takes a Dip: Key Facts
https://www.zacks.com/stock/news/2205270/johnson-johnson-jnj-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2205270
Jan 03, 2024 - In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $160.97, denoting a +0.63% change from the preceding trading day.
0
2 Best Warren Buffett Stocks to Buy for the Long Haul
https://www.fool.com/investing/2023/12/30/2-best-warren-buffett-stocks-to-buy-for-the-long/?source=iedfolrf0000001
Dec 30, 2023 - These companies need no introduction.
0
There Are Only 5 Dow Stocks I Wouldn't Buy in 2024
https://www.fool.com/investing/2023/12/29/there-are-only-5-dow-stocks-i-wouldnt-buy-in-2024/?source=iedfolrf0000001
Dec 29, 2023 - There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024.
0
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
https://www.zacks.com/stock/news/2203479/is-ishares-core-high-dividend-etf-hdv-a-strong-etf-right-now?cid=CS-ZC-FT-smart_beta_etf-2203479
Dec 29, 2023 - Smart Beta ETF report for HDV
0
Can JNJ reverse loss in 2024 on EPS growth, eyes on talc litigation
https://seekingalpha.com/news/4050710-can-jnj-reverse-loss-in-2024-on-eps-growth-eyes-on-talc-litigation?source=feed_sector_healthcare
Dec 27, 2023 - Johnson & Johnson 2024: What to Expect Wells Fargo downgraded Johnson & Johnson (JNJ) to equal weight and lowered PT to $163 from $170 as analyst expects EPS gr
0
Top Stock Reports for JPMorgan, Abbott, Qualcomm & Others
https://www.zacks.com/commentary/2198609/top-stock-reports-for-jpmorgan-abbott-qualcomm-others?cid=CS-ZC-FT-research_daily-2198609
Dec 15, 2023 - Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT) and Qualcomm, Inc. (QCOM).
0
JNJ multiple myeloma therapy outperforms standard of care by 58%
https://seekingalpha.com/news/4045689-jnj-multiple-myeloma-therapy-outperforms-standard-of-care?source=feed_sector_healthcare
Dec 12, 2023 - Johnson & Johnson's (JNJ) multiple myeloma therapy Darzalex Faspro in combination with traditional treatments outperforms standard of care. Read more here.
0
Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?
https://www.zacks.com/stock/news/2196537/should-ishares-core-high-dividend-etf-hdv-be-on-your-investing-radar?cid=CS-ZC-FT-style_box_etf-2196537
Dec 12, 2023 - Style Box ETF report for HDV
0
Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
https://www.zacks.com/stock/news/2195315/pharma-stock-roundup-abbv-to-buy-cere-jnj-s-2024-view-lly-nvs-get-fda-nod?cid=CS-ZC-FT-analyst_blog|stock_roundup-2195315
Dec 08, 2023 - AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
0
Top Analyst Reports for Johnson & Johnson, T-Mobile & Caterpillar
https://www.zacks.com/commentary/2193470/top-analyst-reports-for-johnson-johnson-t-mobile-caterpillar?cid=CS-ZC-FT-research_daily-2193470
Dec 05, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), T-Mobile US, Inc. (TMUS) and Caterpillar Inc. (CAT).
0